pre-IPO PHARMA
COMPANIES VC JOBS NEWS CONTACT

phanes-therapeutics PRESS RELEASE ARCHIVE

Sep 14, 2023

Phanes Therapeutics Announces the Appointment of Internationally Renowned Oncologist Prof. Shun Lu to its Clinical Advisory Board

Sep 7, 2023

Phanes Therapeutics Announces First Patient Dosed in Phase 1 Study of PT217 for Small Cell Lung Cancer and Other Neuroendocrine Cancers Expressing DLL3

Sep 5, 2023

Phanes Therapeutics Announces the Establishment of Oncology Clinical Advisory Board

May 30, 2023

Phanes Therapeutics announces the appointment of Rita Laeufle, MD, PhD, as Chief Medical Officer

Mar 20, 2023

Phanes Therapeutics Announces First Patient Dosed in Phase 1 Study of PT886 for Advanced Gastric, Gastroesophageal Junction and Pancreatic Adenocarcinomas

Mar 6, 2023

PHANES THERAPEUTICS entered into a research collaboration with Xyphos Biosciences, Inc., an Astellas Company

Jan 17, 2023

Phanes Therapeutics' anti-claudin 18.2 antibody patent granted in the US

Dec 8, 2022

Phanes Therapeutics Announces Clinical Supply Agreement with BeiGene to Evaluate PT199 in combination with Tislelizumab

Nov 4, 2022

PHANES THERAPEUTICS TO PRESENT AT BIOFUTURE™ 2022

Oct 14, 2022

Phanes Therapeutics announces FDA IND clearance for PT217, an anti-DLL3/anti-CD47 bispecific antibody being developed for patients with small cell lung cancer and other neuroendocrine cancers

Aug 23, 2022

Phanes Therapeutics Announces First Patient Dosed in Phase 1 Study of PT199 for Advanced Solid Tumors

Aug 2, 2022

Phanes Therapeutics' anti-CD47 antibody patent granted in the US

Jun 30, 2022

Phanes Therapeutics' PT886 granted Orphan Drug Designation for the treatment of pancreatic cancer by the FDA

Jun 21, 2022

Phanes Therapeutics' PT217 receives Orphan Drug Designation for small cell lung cancer from the FDA

Jun 15, 2022

Phanes Therapeutics announces FDA IND clearance for PT886, an anti-claudin18.2/anti-CD47 bispecific antibody being developed for patients with gastric, gastroesophageal junction, and pancreatic cancers

Apr 20, 2022

Phanes Therapeutics revealed manufacturing validation of its bispecific technology platforms PACbody™ and SPECpair™ at AACR 2022

Apr 12, 2022

Phanes Therapeutics' anti-CD73 antibody patent granted in the US

Mar 22, 2022

Phanes Therapeutics announces FDA IND clearance for PT199, a next generation monoclonal antibody against human CD73

Mar 16, 2022

Phanes Therapeutics Announces Three Upcoming Presentations at the 2022 American Association for Cancer Research (AACR) Annual Meeting

Feb 4, 2022

Phanes Therapeutics' antibody patent granted

Jan 11, 2022

Phanes Therapeutics announces the appointment of Vice President of Business Development

Dec 15, 2021

PHANES THERAPEUTICS TO PRESENT AT BIOTECH SHOWCASE™ 2022 IN SAN FRANCISCO

Sep 10, 2021

Phanes Therapeutics reveals SPECpair™ technology platform that enhances manufacturability of bispecific antibodies

May 25, 2021

Phanes Therapeutics Announces $40 million Series B Financing

Jun 16, 2020

Phanes Therapeutics reveals a new bispecific antibody technology platform at BIO Digital 2020

Mar 13, 2018

CrownBio Enters Strategic Partnership with Phanes Therapeutics to Accelerate Discovery and Development of Phanes’ Novel Oncology Agents

Google Analytics Alternative